The metabolic effect of @entity22482 infusion in non-insulin-dependent XXXX @entity1 .

@entity1 @entity2175 @entity844 @entity1133 @entity6 @entity4962 @entity13961 @entity22482 @entity880 @entity10989 @entity18106 @entity413 @entity6178 @entity1718 @entity3363 @entity2388
@entity22482 ( @entity18106 ) is an even-numbered @entity13961 (DA). @entity10989 are water-soluble substances with a metabolic pathway intermediate to those of lipids and @entity3363 . Previous studies showed that contrary to other DAs, very low amounts of @entity18106 are lost with urine. The effects of 46.6 mmol of @entity18106 intravenous infusion for 195 min on blood @entity413 levels were investigated in five @entity1 with @entity2175 ( @entity2175 ), with a good metabolic compensation, and in five healthy volunteers matched for gender, age, and body mass index. Blood samples were taken every 15 min for a period of 360 min to measure @entity413 , insulin, C-peptide, @entity6178 bodies, and free @entity844 (FFA) levels, and 24-h urine samples were collected to measure @entity18106 and @entity1133 excretion. Plasma and urinary @entity18106 concentrations were determined by high-pressure liquid chromatography (HPLC). Indirect calorimetry was continuously performed both basally and during the study period. The average 24-h urinary excretion of @entity18106 was 6.5% versus 6.7% of the administered dose, respectively, in @entity2175 @entity1 and in healthy controls. The area under the curve (AUC) values of plasma @entity18106 were 279.9 +/- 42.7 mumol in @entity2175 @entity1 and 219.7 +/- 14.0 mumol in controls (P = ns). Plasma @entity413 levels significantly decreased in @entity2175 @entity1 during @entity18106 infusion (from 7.8 +/- 0.6 to 5.4 +/- 0.8 mM at the end of the study period, P < 0.05). @entity880 plasma concentration decreased in @entity2175 @entity1 from 3.5 +/- 0.2 to 1.5 +/- 0.1 mM (P < 0.001), whereas blood @entity2388 increased at the end of the experimental session from 26.0 +/- 11.6 to 99.5 +/- 14.9 microM (P < 0.01). Free @entity1718 decreased in @entity6 @entity1 from the beginning until the end of @entity18106 infusion, although this difference did not reach statistical significance. No significant increase was found between basal and final values in @entity4962 consumption and in the values of nonprotein respiratory quotient in both groups of subjects examined. The experimental data indicate that @entity18106 infusion decreases plasma @entity413 levels in @entity2175 @entity1 to normal range without influencing plasma insulin levels. The balance between @entity2388 and @entity880 was affected by @entity18106 infusion only in @entity6 @entity1 . @entity18106 might represent a fuel substrate immediately available for tissue energy requirements, especially in conditions such as @entity6 in which @entity413 metabolism is impaired.
